Correlation between DCE‑MRI radiomics features and Ki‑67 expression in invasive breast cancer

Juan,Ma‑Wen; Yu,Ji; Peng,Guo‑Xin; Jun,Liu‑Jun; Feng,Sun‑Peng; Fang,Liu‑Pei

doi:10.3892/ol.2018.9271

Correlation between DCE‑MRI radiomics features and Ki‑67 expression in invasive breast cancer

Authors:
- Ma‑Wen Juan
- Ji Yu
- Guo‑Xin Peng
- Liu‑Jun Jun
- Sun‑Peng Feng
- Liu‑Pei Fang
View Affiliations

Affiliations: Department of Breast Imaging, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: August 6, 2018 https://doi.org/10.3892/ol.2018.9271
Pages: 5084-5090
Copyright: © Juan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between Ki‑67 expression and radiomics features of dynamic contrast‑enhanced magnetic resonance imaging (DCE‑MRI) in patients with invasive breast cancer. A total of 53 cases with low‑Ki‑67 expression (Ki‑67 proliferation index <14%) and 106 cases with high‑Ki‑67 expression (Ki‑67 proliferation index >14%) were investigated. A systematic approach was applied that focused on the automated segmentation of lesions and extraction of radiomics features. For each lesion 5 morphology, 4 gray‑scale histogram and 6 texture features were obtained, and statistical analyzes were performed to assess the differences in these features between the low‑ and high‑Ki‑67 expressions. One morphology metric (area), 3 gray‑scale histogram indexes (standard deviation, skewness and kurtosis) and 3 texture features (contrast, homogeneity and inverse differential moment) demonstrated a significant difference (P<0.05), with low‑Ki‑67 expression lesions tending to be smaller, clearer and heterogeneous when compared with the high‑Ki‑67 expressed cases. These results may provide a noninvasive means to better understand the proliferation of breast cancer.

View Figures

View References

1	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 138:867–873. 1991.PubMed/NCBI
3	de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
4	Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D and Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
5	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Ealy Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
6	Brown JR, DiGiovanna MP, Killelea B, Lannin DR and Rimm DL: Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest. 94:98–106. 2014. View Article : Google Scholar : PubMed/NCBI
7	Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S and Kuo MD: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl AcadSci USA. 105:5213–5218. 2008. View Article : Google Scholar
8	Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA and Alavi A: Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 38:987–991. 2011. View Article : Google Scholar : PubMed/NCBI
9	Rutman AM and Kuo MD: Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 70:232–241. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yip SS and Aerts HJ: Applications and limitations of radiomics. Phys Med Biol. 61:R150–R166. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A and Aerts HJ: Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer. 48:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, et al: Radiomics: The process and the challenges. Magn Reson Imaging. 30:1234–1248. 2012. View Article : Google Scholar : PubMed/NCBI
13	Limkin EJ, Sun R, Dercle L, Zacharaki EI, Robert C, Reuzé S, Schernberg A, Paragios N, Deutsch E and Ferté C: Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 28:1191–1206. 2017. View Article : Google Scholar : PubMed/NCBI
14	Nie K, Chen JH, Yu HJ, Chu Y, Nalcioglu O and Su MY: Quantitative analysis of lesion morphology and texture features for diagnostic prediction in breast MRI. Acad Radiol. 15:1513–1525. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kim SG, Freed M, Leite APK, Zhang J, Seuss C and Moy L: Separation of benign and malignant breast lesions using dynamic contrast enhanced MRI in a biopsy cohort. J Magn Reson Imaging. 45:1385–1393. 2017. View Article : Google Scholar : PubMed/NCBI
16	Chang RF, Chen HH, Chang YC, Huang CS, Chen JH and Lo CM: Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging. 34:809–819. 2016. View Article : Google Scholar : PubMed/NCBI
17	Fan M, Li H, Wang S, Zheng B, Zhang J and Li L: Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer. PLoS One. 12:e01716832017. View Article : Google Scholar : PubMed/NCBI
18	Chou SS, Gombos EC, Chikarmane SA, Giess CS and Jayender J: Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: Correlating histologic grade and receptor status. J Magn Reson Imaging. 46:1748–1759. 2017. View Article : Google Scholar : PubMed/NCBI
19	Agner SC, Rosen MA, Englander S, Tomaszewski JE, Feldman MD, Zhang P, Mies C, Schnall MD and Madabhushi A: Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: A feasibility study. Radiology. 272:91–99. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sutton EJ, Dashevsky BZ, Oh JH, Veeraraghavan H, Apte AP, Thakur SB, Morris EA and Deasy JO: Breast cancer molecular subtype classifier that incorporates MRI features. J Magn Reson Imaging. 44:122–129. 2016. View Article : Google Scholar : PubMed/NCBI
21	Lankton S and Tannenbaum A: Localizing region-based active contours. IEEE Trans Image Process. 17:2029–2039. 2008. View Article : Google Scholar : PubMed/NCBI
22	Rodenacker K and Bengtsson E: A feature set for cytometry on digitized microscopic images. Anal Cell Pathol. 25:1–36. 2003. View Article : Google Scholar : PubMed/NCBI
23	Haralick R, Shanmugam K and Dinstein I: Texture parameters for image classification. IEEE Trans SMC. 3:610–621. 1973.
24	Matsubara N, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S and Wada N: Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 147:95–102. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li H, Han X, Liu Y, Liu G and Dong G: Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. Oncol Lett. 9:149–152. 2015. View Article : Google Scholar : PubMed/NCBI